[{"from": "human", "value": "Provide a description of this molecule. [C][C][N][Branch2][Ring1][=N][C][C][N][Ring1][=Branch1][C][C][C][=C][Branch1][P][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][C][C][=Branch1][C][=O][N][Ring1][#Branch1][Cl][C][=N][S][C][=C][C][=C][C][=C][Ring1][=Branch1][Ring1][=Branch2]"}, {"from": "gpt", "value": "The molecule are generally thought to be as efficacious as first generation antipsychotics but differ in their adverse effect profiles. First generation antipsychotics are associated with extrapyramidal adverse effects while atypical antipsychotics are linked to weight gain, impaired glucose tolerance and metabolic syndrome.   Ziprasidone is used to treat schizophrenia and bipolar disorder. It can effectively reduce the rate and time of relapses in schizophrenia, and can be used to treat manic episodes in bipolar disorder although the mechanism of action is unknown. Although ziprasidone is classified as an atypical antipsychotic, it appears to have a lower incidence of metabolic adverse effects compared to other medications in the same class."}]